Core Viewpoint - Ekso Bionics Holdings, Inc. has entered into a private placement agreement to raise approximately $5.9 million through the sale of Series B Preferred Stock and warrants, aimed at enhancing its working capital and corporate purposes [1][3]. Group 1: Private Placement Details - The company will sell 5,852 shares of Series B Preferred Stock with a stated value of $1,000 per share, convertible into 711,922 shares of common stock at a conversion price of $8.22 per share [2]. - The warrants will allow the purchase of up to 355,960 shares of common stock at an exercise price of $8.22 per share, expiring five years from the initial exercise date [2]. - The closing of the private placement is expected around January 22, 2026, pending customary closing conditions [3]. Group 2: Financial Implications - The gross proceeds from the private placement are anticipated to be approximately $5.9 million before deducting fees and expenses [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]. - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7].

Core Points - Ekso Bionics Holdings, Inc. will implement a reverse stock split at a ratio of 1-for-15, effective May 27, 2025 [1][3] - The number of outstanding shares will decrease from approximately 35,289,695 to about 2,352,646 post-split [2] - The reverse stock split aims to raise the per share trading price to comply with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Shareholder Impact - No fractional shares will be issued; any fractional shares will be rounded up to the next whole share [4] - The reverse stock split will uniformly affect all shareholders without significantly altering their percentage interest in the company's equity [5] - Stock options and restricted stock units will be adjusted accordingly, with a corresponding increase in exercise prices [5] Administrative Details - Shareholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] - Additional information regarding the reverse stock split is available in the Company's Definitive Proxy Statement filed with the SEC [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7] - The company focuses on improving health and quality of life through advanced robotics designed to restore human function [7] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7]